Soligenix (SNGX) News Today $3.52 -0.02 (-0.56%) (As of 11/18/2024 ET) Add Compare Share Share Headlines Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Soligenix initiates Phase 2 clinical trial of SGX945 in Behcet’s DiseaseNovember 15, 2024 | markets.businessinsider.comSOLIGENIX, INC.: Soligenix Initiates a Phase 2 Clinical Trial of SGX945 (dusquetide) for the treatment of Behçet's DiseaseNovember 14, 2024 | finanznachrichten.deSoligenix Initiates a Phase 2 Clinical Trial of SGX945 (dusquetide) for the treatment of Behçet's DiseaseNovember 14, 2024 | prnewswire.comSNGX: Phase 3 CTCL Trial to Initiate Before End of 2024November 12, 2024 | finance.yahoo.comSoligenix Announces Recent Accomplishments And Third Quarter 2024 Financial ResultsNovember 8, 2024 | prnewswire.comSoligenix gains Hong Kong patent for synthetic hypericinOctober 25, 2024 | investing.comSoligenix, Inc. to Present at the 2024 ThinkEquity ConferenceOctober 24, 2024 | globenewswire.comSoligenix granted Hong Kong patent for production of synthetic hypericinOctober 23, 2024 | markets.businessinsider.comSoligenix Receives Hong Kong Patent for Improved Production of Synthetic HypericinOctober 22, 2024 | prnewswire.comSoligenix Invited to Present at Upcoming Investor ConferencesOctober 16, 2024 | prnewswire.comHyBryte™ Expanded Treatment Results to be Presented at the European Organisation for Research and Treatment of Cancer ConferenceOctober 7, 2024 | prnewswire.comSNGX: Marburg Outbreak Puts Focus on Soligenix Vaccine Development…October 3, 2024 | msn.comSoligenix (NASDAQ:SNGX) Stock Quotes, Forecast and News SummaryOctober 3, 2024 | benzinga.comSoligenix, Sterling Pharma Partner To Develop Production Technology For Synthetic HypericinOctober 3, 2024 | markets.businessinsider.comSoligenix Announces Partnership with Sterling Pharma SolutionsOctober 3, 2024 | prnewswire.comJoin Soligenix's Exclusive Live Investor Webinar and Q&A Session on September 18, 2024September 16, 2024 | prnewswire.comSoligenix Receives European Patent for Improved Production of Synthetic HypericinSeptember 3, 2024 | prnewswire.comSNGX: Phase 3 Trial of HyBryte™ in CTCL to Initiate in 2H24…August 13, 2024 | finance.yahoo.comSoligenix Second Quarter 2024 Earnings: EPS Beats Expectations, Revenues LagAugust 13, 2024 | uk.finance.yahoo.comSOLIGENIX, INC.: Soligenix Announces Recent Accomplishments And Second Quarter 2024 Financial ResultsAugust 9, 2024 | finanznachrichten.deSoligenix Trumpets Q2 NumbersAugust 9, 2024 | baystreet.caSoligenix Announces Recent Accomplishments And Second Quarter 2024 Financial ResultsAugust 9, 2024 | prnewswire.comStrong Clinical Momentum for Soligenix's HyBryte™ in Treating Cutaneous T-Cell Lymphoma; PCG Digital Exclusive with Dr. Brian PoligoneAugust 1, 2024 | finance.yahoo.comMarketBeat Week in Review – 7/8 - 7/12 (SNGX)Stocks took investors on quite a ride this week, with the S&P 500 hitting a new record high, then falling back on Thursday before rallying to end the weekJuly 13, 2024 | marketbeat.comUncover Why This Pharma Stock Jumped 400% on Study UpdateSoligenix Inc. NASDAQ: SNGX, a late-stage biopharmaceutical company, experienced an astonishing surge Tuesday. At the time of writing, the stock had soared nearly 400%.July 10, 2024 | marketbeat.comUncover Why This Pharma Stock Jumped 400% on Study UpdateShares of Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company, surged almost 400% today after announcing positive data.July 10, 2024 | marketbeat.com5 Investors Betting Big on Soligenix (SNGX) StockJuly 9, 2024 | investorplace.comWhy Is Soligenix (SNGX) Stock Up 296% Today?July 9, 2024 | investorplace.comExpanded HyBryte™ Treatment Demonstrating Positive Outcomes in Early-Stage Cutaneous T-Cell LymphomaJuly 9, 2024 | prnewswire.comSoligenix Announces Positive Clinical Results from a Comparative Study Evaluating HyBryte™ Against Valchlor® in the Treatment of Cutaneous T-Cell LymphomaJune 25, 2024 | prnewswire.comA Comparison of Vaccine Technologies to be Presented at the ASM Microbe ConferenceJune 14, 2024 | prnewswire.comSoligenix Announces Reverse Stock SplitMay 31, 2024 | prnewswire.comSoligenix Encourages Stockholders to Vote their Shares at the Annual MeetingMay 29, 2024 | prnewswire.comSoligenix, Inc. Announces Adjournment of Annual Meeting, Information for Reconvened Annual MeetingMay 24, 2024 | prnewswire.comSoligenix Encourages Stockholders to Vote "FOR" Reverse Stock SplitMay 23, 2024 | prnewswire.comSoligenix, Inc. (SNGX)May 22, 2024 | finance.yahoo.comPRISM MarketView Highlights Soligenix, Inc. as it Builds on Compelling Phase 3 Data with Key Catalysts on the HorizonMay 21, 2024 | finance.yahoo.comSuVax™ and MarVax™ Thermostable Vaccine Platform to be Presented at the Vaccine Technology IX ConferenceMay 21, 2024 | prnewswire.comSoligenix Encourages Stockholders to Vote Prior to Annual MeetingMay 20, 2024 | prnewswire.comPositive Clinical Results from HyBryte™ Compatibility Study in the Treatment of Cutaneous T-Cell Lymphoma Published in JEADV Clinical PracticeMay 16, 2024 | prnewswire.comSNGX: Second Confirmatory Phase 3 Trial of HyBryte™ in CTCL to Initiate Before End of 2024…May 14, 2024 | finance.yahoo.comSNGX Stock Earnings: Soligenix Beats EPS, Misses Revenue for Q1 2024May 13, 2024 | msn.comSoligenix First Quarter 2024 Earnings: EPS Beats Expectations, Revenues LagMay 13, 2024 | finance.yahoo.comSoligenix Announces Recent Accomplishments And First Quarter 2024 Financial ResultsMay 10, 2024 | prnewswire.comSoligenix to Present at Upcoming ConferencesMay 6, 2024 | prnewswire.comSoligenix Extends Patent Protection for its Filovirus Vaccine Platform to the United Kingdom and South AfricaApril 25, 2024 | prnewswire.comSoligenix Announces Pricing of $4.75 Million Public OfferingApril 18, 2024 | prnewswire.comSoligenix gains orphan drug status for MarVax vaccineApril 17, 2024 | investing.comSage Therapeutics' Parkinson's drug fails in mid-stage studyApril 17, 2024 | finance.yahoo.comNanoscope Therapeutics to Present at the World Orphan Drug Congress 2024April 17, 2024 | finance.yahoo.com Get Soligenix News Delivered to You Automatically Sign up to receive the latest news and ratings for SNGX and its competitors with MarketBeat's FREE daily newsletter. Email Address My Top Trump Rally Stocks (Ad)This Catalyst Hits Once Every 4 Years.. Every four years, on the day of the election, a catalyst is triggered. Over the last 20 years, this catalyst has caused 1,500 stocks to rise an average of 3,700%... within 90 days. And now, Tim Bohen is blowing the whole story wide open on Wednesday, November 20th at 8PM. Click here for details on your FREE RSVP. SNGX Media Mentions By Week SNGX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SNGX News Sentiment▼0.430.57▲Average Medical News Sentiment SNGX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SNGX Articles This Week▼82▲SNGX Articles Average Week Get Soligenix News Delivered to You Automatically Sign up to receive the latest news and ratings for SNGX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Marker Therapeutics News Today Longeveron News Today KALA BIO News Today Eyenovia News Today Surrozen News Today Acasti Pharma News Today LianBio News Today BioVie News Today MiNK Therapeutics News Today Athira Pharma News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SNGX) was last updated on 11/19/2024 by MarketBeat.com Staff From Our PartnersTop "Sleeping Giant" Crypto In The Market NowTop "Sleeping Giant" Crypto In The Market Now We're looking at potential returns that could rewrite your fi...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist My Default Watchlist Adding Soligenix, Inc. You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Please log in to your account or sign up in order to add this asset to your watchlist. Share Soligenix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
